person · Reporting owner

Lewis-Hall Freda C

Disclosed activity across 7 companies

Tapewire entity: 16005
SEC CIK: 0001437909

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CDT Equity Inc.CDT · Entity 1035	Director	August 05, 2025	August 26, 2025
EXACT SCIENCES CORPEXAS · Entity 56619	Director	June 08, 2023	June 12, 2023
PFIZER INCPFE · Entity 2863	Executive Vice President	February 27, 2019	March 02, 2019
Pyxis Oncology, Inc.PYXS · Entity 5986	Director	March 24, 2026	March 25, 2026
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875	EVP, Medicines Development	March 19, 2009	March 20, 2009

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CDT Equity Inc.

Report date August 05, 2025 · Filed August 26, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	38,466	Reported balance After 2025-08-12 transaction · row 1 1 source row Row 1 · 2025-08-12 · Grant · Acquired 35,000 · Balance 38,466 F1: Represents restricted stock units ("RSUs") received on August 12, 2025, in exchange for past services, having a value equal to approximately $60,900 based on the closing price per share of the Issuer's common stock on August 12, 2025. The RSUs vest immediately upon grant.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.89 · Expires 2035-08-05	Direct	15,000	Reported balance After 2025-08-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-08-05 · Grant · Acquired 15,000 · Balance 15,000 F4: Represents options to purchase common stock, granted under the Issuer's 2023 Stock Incentive Plan, which were granted at the conclusion of the Issuer's 2025 annual meeting of stockholders. F5: The options vest immediately upon grant.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,335	Reported balance Holding disclosure · report date 2025-08-05 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,335 F2: The shares are held of record by Intelmed LLC ("Intelmed"). Ms. Lewis-Hall is the Managing Director of Intelmed and in such capacity has voting and investment discretion with respect to the shares held of record by Intelmed. By virtue of this relationship, Ms. Lewis-Hall may be deemed to share beneficial ownership of the shares held of record by Intelmed. Ms. Lewis-Hall disclaims any such beneficial ownership except to the extent of her pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	344	Reported balance Holding disclosure · report date 2025-08-05 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 344 F3: The shares are held by Ms. Lewis-Hall's spouse, Mr. Emerson Hall, Jr. As Mr. Hall's spouse and by virtue of their relationship, Ms. Lewis-Hall may be deemed to share beneficial ownership of such shares held by record by Mr. Emerson Hall, Jr. Ms. Lewis-Hall disclaims any such beneficial ownership except to the extent of her pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units ("RSUs") received on August 12, 2025, in exchange for past services, having a value equal to approximately $60,900 based on the closing price per share of the Issuer's common stock on August 12, 2025. The RSUs vest immediately upon grant.

F2: The shares are held of record by Intelmed LLC ("Intelmed"). Ms. Lewis-Hall is the Managing Director of Intelmed and in such capacity has voting and investment discretion with respect to the shares held of record by Intelmed. By virtue of this relationship, Ms. Lewis-Hall may be deemed to share beneficial ownership of the shares held of record by Intelmed. Ms. Lewis-Hall disclaims any such beneficial ownership except to the extent of her pecuniary interest therein.

F3: The shares are held by Ms. Lewis-Hall's spouse, Mr. Emerson Hall, Jr. As Mr. Hall's spouse and by virtue of their relationship, Ms. Lewis-Hall may be deemed to share beneficial ownership of such shares held by record by Mr. Emerson Hall, Jr. Ms. Lewis-Hall disclaims any such beneficial ownership except to the extent of her pecuniary interest therein.

F4: Represents options to purchase common stock, granted under the Issuer's 2023 Stock Incentive Plan, which were granted at the conclusion of the Issuer's 2025 annual meeting of stockholders.

F5: The options vest immediately upon grant.

EXACT SCIENCES CORP

Report date June 08, 2023 · Filed June 12, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	19,688	Reported balance After 2023-06-08 transaction · row 1 1 source row Row 1 · 2023-06-08 · Grant · Acquired 3,599 · Balance 19,688 F1: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy.

Filing footnotes · ownership attribution and instrument terms

F1: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy.

PFIZER INC

Report date February 27, 2019 · Filed March 02, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	375,244	Ending reported balance After 2019-02-27 transaction · row 5 5 source rows · reconciled sequence Row 1 · 2019-02-27 · Exercise / conversion · Acquired 81,475 · Balance 416,278 F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Row 2 · 2019-02-27 · Grant · Acquired 48,092 · Balance 464,370 F2: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Row 3 · 2019-02-27 · Tax withholding · Disposed 15,258 · Balance 449,112 F3: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Row 4 · 2019-02-27 · Tax withholding · Disposed 23,551 · Balance 425,561 F4: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Row 5 · 2019-02-27 · Tax withholding · Disposed 50,317 · Balance 375,244 F5: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F6: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $32.23 · Expires 2019-02-27	Direct	0	Reported balance After 2019-02-27 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-02-27 · Exercise / conversion · Disposed 81,475 · Balance 0
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $43.35 · Expires 2024-02-28	Direct	54,151	Reported balance After 2019-02-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-02-28 · Grant · Acquired 54,151 · Balance 54,151 F7: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $43.35 · Expires 2026-02-28	Direct	45,634	Reported balance After 2019-02-28 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-02-28 · Grant · Acquired 45,634 · Balance 45,634 F8: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.
Common StockSEC Table I · non-derivative	IndirectBy Rule 16b-3 Plan	4,320	Reported balance Holding disclosure · report date 2019-02-27 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 4,320

Filing footnotes · ownership attribution and instrument terms

F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

F2: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon).

F3: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F4: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon).

F5: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F6: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

F7: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F8: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

Pyxis Oncology, Inc.

Report date March 24, 2026 · Filed March 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-03-24	Direct	45,867	Reported balance After 2026-03-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-03-24 · Grant · Acquired 45,867 · Balance 45,867 F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

VERTEX PHARMACEUTICALS INC / MA

Report date March 19, 2009 · Filed March 20, 2009

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	53,334	Reported balance After 2009-03-19 transaction · row 1 1 source row Row 1 · 2009-03-19 · Sale · Disposed 1,250 · Balance 53,334 F1: Transaction made pursuant to Dr. Lewis-Hall's company approved trading plan established under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $29.11 (range $28.85 to $29.78). F3: Dr. Lewis-Hall undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction made pursuant to Dr. Lewis-Hall's company approved trading plan established under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $29.11 (range $28.85 to $29.78).

F3: Dr. Lewis-Hall undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

1Life Healthcare Inc

Report date February 22, 2023 · Filed February 24, 2023

Section 16 reporting ended · disclosed 2023-02-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-02-22 transaction · row 1 1 source row Row 1 · 2023-02-22 · Disposition to issuer · Disposed 4,534 · Balance 0 F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 20, 2022, by and among Issuer, Amazon.com, Inc. ("Parent") and Negroni Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on February 22, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of Issuer common stock, par value $0.001 per share ("Shares") issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive $18.00 in cash, without interest (the "Merger Consideration").
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.56 · Expires 2029-11-20	Direct	Reported balance After 2023-02-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-02-22 · Disposition to issuer · Disposed 10,381 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding option ("Option") to purchase Shares granted under any of the Issuer's 2007 Equity Incentive Plan, 2017 Equity Incentive Plan, 2020 Equity Incentive Plan and the Iora Third Amended and Restated 2011 Equity Incentive Plan (collective, the "Issuer Stock Plans") or portion thereof that was vested or became vested as of the Effective Time, and had an exercise price per Share that is less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such Option and (ii) the aggregate number of Shares issuable upon exercise of such Option or portion thereof, subject to any required withholding of taxes. F3: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the first anniversary of the vesting commencement date; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years, subject to reporting person's continuous service as of each such date. At the Effective Time, any unvested shares subject to the option was accelerated in full.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.00 · Expires 2030-05-13	Direct	Reported balance After 2023-02-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-02-22 · Disposition to issuer · Disposed 5,294 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each Option, whether vested or unvested, that has an exercise price per Share that is greater than the Merger Consideration was canceled without the payment of consideration. F5: The shares subject to the option are fully vested and immediately exercisable.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-02-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-02-22 · Disposition to issuer · Disposed 20,728 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock. RSUs convert into the issuer's common stock on a one-for-one basis. F7: The RSUs vest on the earlier of (i) the date of the issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the reporting person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant. At the Effective Time, each outstanding RSU that was unvested was accelerated in full and was automatically converted in to the right to receive the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 20, 2022, by and among Issuer, Amazon.com, Inc. ("Parent") and Negroni Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on February 22, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of Issuer common stock, par value $0.001 per share ("Shares") issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive $18.00 in cash, without interest (the "Merger Consideration").

F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding option ("Option") to purchase Shares granted under any of the Issuer's 2007 Equity Incentive Plan, 2017 Equity Incentive Plan, 2020 Equity Incentive Plan and the Iora Third Amended and Restated 2011 Equity Incentive Plan (collective, the "Issuer Stock Plans") or portion thereof that was vested or became vested as of the Effective Time, and had an exercise price per Share that is less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such Option and (ii) the aggregate number of Shares issuable upon exercise of such Option or portion thereof, subject to any required withholding of taxes.

F3: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the first anniversary of the vesting commencement date; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years, subject to reporting person's continuous service as of each such date. At the Effective Time, any unvested shares subject to the option was accelerated in full.

F4: Pursuant to the Merger Agreement, at the Effective Time, each Option, whether vested or unvested, that has an exercise price per Share that is greater than the Merger Consideration was canceled without the payment of consideration.

F5: The shares subject to the option are fully vested and immediately exercisable.

F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock. RSUs convert into the issuer's common stock on a one-for-one basis.

F7: The RSUs vest on the earlier of (i) the date of the issuer's next annual meeting of stockholders (or the date immediately prior to the next annual meeting of stockholders if the reporting person's service as a director ends at such meeting due to the director's failure to be re-elected or the director not standing for re-election); or (ii) the one-year anniversary measured from the date of grant. At the Effective Time, each outstanding RSU that was unvested was accelerated in full and was automatically converted in to the right to receive the Merger Consideration.

SpringWorks Therapeutics, Inc.

Report date July 01, 2025 · Filed July 02, 2025

Section 16 reporting ended · disclosed 2025-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-07-01 transaction · row 1 1 source row Row 1 · 2025-07-01 · Disposition to issuer · Disposed 24,727 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F2: Includes 10,060 shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock. F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration"). F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00	Direct	Reported balance After 2025-07-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-07-01 · Disposition to issuer · Disposed 29,983 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6) F6: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.03	Direct	Reported balance After 2025-07-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-07-01 · Disposition to issuer · Disposed 7,464 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6) F6: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.42	Direct	Reported balance After 2025-07-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-07-01 · Disposition to issuer · Disposed 15,318 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6) F6: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.27	Direct	Reported balance After 2025-07-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-07-01 · Disposition to issuer · Disposed 13,774 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6) F6: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.77	Direct	Reported balance After 2025-07-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-07-01 · Disposition to issuer · Disposed 12,216 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6) F6: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger").

F2: Includes 10,060 shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock.

F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration").

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)

F6: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 17, 2019 Filed Sep 19, 2019 19:12 UTC	SpringWorks Therapeutics, Inc. SWTX · Entity 15910	ConversionCommon Stock	978,194	Not disclosed	Not disclosed	Disclosure SEC source: 0001144204-19-045298 · tv529791_form4.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By: Pfizer Inc. Disclosed balance after: 978,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Junior Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Junior Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Junior Series A Convertible Preferred Stock has no expiration date. F4 · ownership.nature: Shares held by Pfizer Inc. ("Pfizer"). The reporting person is employed by Pfizer. The reporting person has no voting or dispositive power over the shares held by Pfizer or Pfizer Ventures (US) Holdings ("Pfizer Ventures"), a wholly owned subsidiary of Pfizer, and disclaims beneficial ownership of all such shares. Read SEC document
September 12, 2019 Filed Sep 16, 2019 20:47 UTC	SpringWorks Therapeutics, Inc. SWTX · Entity 15910	GrantStock Option (Right to Buy) · Derivative	29,983	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001144204-19-044793 · tv529542_form4.xml · derivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,983 Underlying: Common Stock · 29,983 shares Expires 2029-09-12 F1 · derivative.exercise_date: This option shall vest in equal monthly installments over the period of thirty six (36) months following September 12, 2019, subject to continued service to the Issuer on each vesting date. Read SEC document
March 29, 2019 Filed Sep 16, 2019 20:47 UTC	SpringWorks Therapeutics, Inc. SWTX · Entity 15910	GrantSeries B Convertible Preferred Stock · Derivative	3,465,571	Not disclosed	Not disclosed	Disclosure SEC source: 0001144204-19-044793 · tv529542_form4.xml · derivative · entry 4 Lewis-Hall Freda C · CIK 0001437909 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Pfizer Ventures (US) LLC Disclosed balance after: 526,602 Underlying: Common Stock · 526,602 shares Expires not disclosed F5 · derivative.exercise_price: On March 29, 2019, Pfizer Ventures acquired 3,465,571 shares of Series B Convertible Preferred Stock of the Issuer. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. F5 · price: On March 29, 2019, Pfizer Ventures acquired 3,465,571 shares of Series B Convertible Preferred Stock of the Issuer. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. F5 · derivative.exercise_date: On March 29, 2019, Pfizer Ventures acquired 3,465,571 shares of Series B Convertible Preferred Stock of the Issuer. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. F5 · derivative.expiration_date: On March 29, 2019, Pfizer Ventures acquired 3,465,571 shares of Series B Convertible Preferred Stock of the Issuer. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. F6 · ownership.nature: Shares held by Pfizer Ventures. The reporting person is employed by Pfizer. The reporting person has no voting or dispositive power over the shares held by Pfizer or Pfizer Ventures and disclaims beneficial ownership of all such shares. Read SEC document
March 29, 2019 Filed Sep 16, 2019 20:47 UTC	SpringWorks Therapeutics, Inc. SWTX · Entity 15910	GrantSeries A Convertible Preferred Stock · Derivative	20,000,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001144204-19-044793 · tv529542_form4.xml · derivative · entry 3 Lewis-Hall Freda C · CIK 0001437909 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Pfizer Inc. Disclosed balance after: 3,039,051 Underlying: Common Stock · 3,039,051 shares Expires not disclosed F4 · derivative.exercise_price: On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, Pfizer received 20,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date. F4 · price: On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, Pfizer received 20,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date. F4 · derivative.exercise_date: On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, Pfizer received 20,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date. F4 · derivative.expiration_date: On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, Pfizer received 20,000,000 shares of Series A Convertible Preferred Stock of the Issuer. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date. F3 · ownership.nature: Shares held by Pfizer. The reporting person is employed by Pfizer. The reporting person has no voting or dispositive power over the shares held by Pfizer or Pfizer Ventures (US) Holdings ("Pfizer Ventures"), a wholly owned subsidiary of Pfizer, and disclaims beneficial ownership of all such shares. Read SEC document
March 29, 2019 Filed Sep 16, 2019 20:47 UTC	SpringWorks Therapeutics, Inc. SWTX · Entity 15910	GrantJunior Series A Convertible Preferred Stock · Derivative	6,437,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001144204-19-044793 · tv529542_form4.xml · derivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Pfizer Inc. Disclosed balance after: 978,194 Underlying: Common Stock · 978,194 shares Expires not disclosed F2 · derivative.exercise_price: On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, Pfizer Inc. ("Pfizer") received 6,437,500 shares of Junior Series A Convertible Preferred Stock of the Issuer. Each share of Junior Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Junior Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Junior Series A Convertible Preferred Stock has no expiration date. F2 · price: On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, Pfizer Inc. ("Pfizer") received 6,437,500 shares of Junior Series A Convertible Preferred Stock of the Issuer. Each share of Junior Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Junior Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Junior Series A Convertible Preferred Stock has no expiration date. F2 · derivative.exercise_date: On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, Pfizer Inc. ("Pfizer") received 6,437,500 shares of Junior Series A Convertible Preferred Stock of the Issuer. Each share of Junior Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Junior Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Junior Series A Convertible Preferred Stock has no expiration date. F2 · derivative.expiration_date: On March 29, 2019, pursuant to a corporate reorganization, all of the equity interests in SpringWorks Therapeutics, LLC were exchanged for the same number and class of newly issued securities of SpringWorks Therapeutics, Inc. Pursuant to the reorganization, Pfizer Inc. ("Pfizer") received 6,437,500 shares of Junior Series A Convertible Preferred Stock of the Issuer. Each share of Junior Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Immediately prior to the closing of the Issuer's initial public offering, all shares of Junior Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Junior Series A Convertible Preferred Stock has no expiration date. F3 · ownership.nature: Shares held by Pfizer. The reporting person is employed by Pfizer. The reporting person has no voting or dispositive power over the shares held by Pfizer or Pfizer Ventures (US) Holdings ("Pfizer Ventures"), a wholly owned subsidiary of Pfizer, and disclaims beneficial ownership of all such shares. Read SEC document
February 28, 2019 Filed Mar 2, 2019 00:37 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	45,634	$0.00 Strike: $43.35	$0.00	Disclosure SEC source: 0001225208-19-004215 · doc4.xml · derivative · entry 9 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,634 Underlying: Common Stock · 45,634 shares Expires 2026-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document
February 28, 2019 Filed Mar 2, 2019 00:37 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	54,151	$0.00 Strike: $43.35	$0.00	Disclosure SEC source: 0001225208-19-004215 · doc4.xml · derivative · entry 8 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,151 Underlying: Common Stock · 54,151 shares Expires 2024-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document
February 27, 2019 Filed Mar 2, 2019 00:37 UTC	PFIZER INC PFE · Entity 2863	Exercise / conversionStock Appreciation Rights · Derivative	81,475	$0.00 Strike: $32.23	$0.00	Disclosure SEC source: 0001225208-19-004215 · doc4.xml · derivative · entry 7 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 81,475 shares Expires 2019-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 27, 2019 Filed Mar 2, 2019 00:37 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	50,317	$42.31	$2,128,912.27	Disclosure SEC source: 0001225208-19-004215 · doc4.xml · nonDerivative · entry 5 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,244 F5 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F6 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document
February 27, 2019 Filed Mar 2, 2019 00:37 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	23,551	$42.93	$1,011,044.43	Disclosure SEC source: 0001225208-19-004215 · doc4.xml · nonDerivative · entry 4 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,561 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 27, 2019 Filed Mar 2, 2019 00:37 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	15,258	$42.93	$655,025.94	Disclosure SEC source: 0001225208-19-004215 · doc4.xml · nonDerivative · entry 3 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,112 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document
February 27, 2019 Filed Mar 2, 2019 00:37 UTC	PFIZER INC PFE · Entity 2863	GrantCommon Stock	48,092	$0.00	$0.00	Disclosure SEC source: 0001225208-19-004215 · doc4.xml · nonDerivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,370 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 27, 2019 Filed Mar 2, 2019 00:37 UTC	PFIZER INC PFE · Entity 2863	Exercise / conversionCommon Stock	81,475	$32.23	$2,625,939.25	Disclosure SEC source: 0001225208-19-004215 · doc4.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document
February 23, 2019 Filed Feb 27, 2019 00:45 UTC	PFIZER INC PFE · Entity 2863	Exercise / conversionStock Appreciation Rights · Derivative	87,449	$0.00 Strike: $21.03	$0.00	Disclosure SEC source: 0001225208-19-003781 · doc4.xml · derivative · entry 5 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,449 shares Expires 2019-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 23, 2019 Filed Feb 27, 2019 00:45 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	27,230	$41.91	$1,141,209.30	Disclosure SEC source: 0001225208-19-003781 · doc4.xml · nonDerivative · entry 3 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,803 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document
February 23, 2019 Filed Feb 27, 2019 00:45 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	25,991	$42.96	$1,116,573.36	Disclosure SEC source: 0001225208-19-003781 · doc4.xml · nonDerivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,033 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 22, 2019 Read SEC document
February 23, 2019 Filed Feb 27, 2019 00:45 UTC	PFIZER INC PFE · Entity 2863	Exercise / conversionCommon Stock	87,449	$21.03	$1,839,052.47	Disclosure SEC source: 0001225208-19-003781 · doc4.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document
February 28, 2018 Filed Mar 2, 2018 20:44 UTC	PFIZER INC PFE · Entity 2863	Exercise / conversionStock Appreciation Rights · Derivative	104,626	$0.00 Strike: $27.37	$0.00	Disclosure SEC source: 0001225208-18-005101 · doc4.xml · derivative · entry 5 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 104,626 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 28, 2018 Filed Mar 2, 2018 20:44 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	63,508	$35.70	$2,267,235.60	Disclosure SEC source: 0001225208-18-005101 · doc4.xml · nonDerivative · entry 3 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,575 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document
February 28, 2018 Filed Mar 2, 2018 20:44 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	20,136	$36.31	$731,138.16	Disclosure SEC source: 0001225208-18-005101 · doc4.xml · nonDerivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,083 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations and payment of exercise price in connection with the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document
February 28, 2018 Filed Mar 2, 2018 20:44 UTC	PFIZER INC PFE · Entity 2863	Exercise / conversionCommon Stock	104,626	$27.37	$2,863,613.62	Disclosure SEC source: 0001225208-18-005101 · doc4.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document
February 26, 2018 Filed Feb 28, 2018 23:09 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	21,078	$37.09	$781,783.02	Disclosure SEC source: 0001225208-18-004665 · doc4.xml · nonDerivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,593 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 26, 2018 Filed Feb 28, 2018 23:09 UTC	PFIZER INC PFE · Entity 2863	GrantCommon Stock	43,042	$0.00	$0.00	Disclosure SEC source: 0001225208-18-004665 · doc4.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,671 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 24, 2018 Filed Feb 28, 2018 00:43 UTC	PFIZER INC PFE · Entity 2863	Exercise / conversionStock Appreciation Rights · Derivative	91,876	$0.00 Strike: $18.90	$0.00	Disclosure SEC source: 0001225208-18-004464 · doc4.xml · derivative · entry 5 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 91,876 shares Expires 2018-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 24, 2018 Filed Feb 28, 2018 00:43 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	29,315	$35.98	$1,054,753.70	Disclosure SEC source: 0001225208-18-004464 · doc4.xml · nonDerivative · entry 3 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,629 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document
February 24, 2018 Filed Feb 28, 2018 00:43 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	26,555	$36.26	$962,884.30	Disclosure SEC source: 0001225208-18-004464 · doc4.xml · nonDerivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,944 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 23, 2018 Read SEC document
February 24, 2018 Filed Feb 28, 2018 00:43 UTC	PFIZER INC PFE · Entity 2863	Exercise / conversionCommon Stock	91,876	$18.90	$1,736,456.40	Disclosure SEC source: 0001225208-18-004464 · doc4.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document
February 22, 2018 Filed Feb 23, 2018 20:50 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	54,356	$0.00 Strike: $35.74	$0.00	Disclosure SEC source: 0001225208-18-003972 · doc4.xml · derivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,356 Underlying: Common Stock · 54,356 shares Expires 2025-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document
February 22, 2018 Filed Feb 23, 2018 20:50 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	65,018	$0.00 Strike: $35.74	$0.00	Disclosure SEC source: 0001225208-18-003972 · doc4.xml · derivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,018 Underlying: Common Stock · 65,018 shares Expires 2023-02-22 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document
February 27, 2017 Filed Mar 1, 2017 22:10 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	8,515	$34.28	$291,894.20	Disclosure SEC source: 0001225208-17-005105 · doc4.xml · nonDerivative · entry 3 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,623 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document
February 27, 2017 Filed Mar 1, 2017 22:10 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	8,421	$34.28	$288,671.88	Disclosure SEC source: 0001225208-17-005105 · doc4.xml · nonDerivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,138 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 27, 2017 Filed Mar 1, 2017 22:10 UTC	PFIZER INC PFE · Entity 2863	GrantCommon Stock	16,329	$0.00	$0.00	Disclosure SEC source: 0001225208-17-005105 · doc4.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,559 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 23, 2017 Filed Feb 27, 2017 23:30 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	60,647	$0.00 Strike: $34.06	$0.00	Disclosure SEC source: 0001225208-17-004775 · doc4.xml · derivative · entry 7 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,647 Underlying: Common Stock · 60,647 shares Expires 2024-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document
February 23, 2017 Filed Feb 27, 2017 23:30 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	73,052	$0.00 Strike: $34.06	$0.00	Disclosure SEC source: 0001225208-17-004775 · doc4.xml · derivative · entry 6 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,052 Underlying: Common Stock · 73,052 shares Expires 2022-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document
February 23, 2017 Filed Feb 27, 2017 23:30 UTC	PFIZER INC PFE · Entity 2863	Exercise / conversionStock Appreciation Rights · Derivative	103,155	$0.00 Strike: $21.03	$0.00	Disclosure SEC source: 0001225208-17-004775 · doc4.xml · derivative · entry 5 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,155 shares Expires 2017-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 23, 2017 Filed Feb 27, 2017 23:30 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	49,942	$32.49	$1,622,615.58	Disclosure SEC source: 0001225208-17-004775 · doc4.xml · nonDerivative · entry 3 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,230 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document
February 23, 2017 Filed Feb 27, 2017 23:30 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	23,184	$34.06	$789,647.04	Disclosure SEC source: 0001225208-17-004775 · doc4.xml · nonDerivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,172 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document
February 23, 2017 Filed Feb 27, 2017 23:30 UTC	PFIZER INC PFE · Entity 2863	Exercise / conversionCommon Stock	103,155	$21.03	$2,169,349.65	Disclosure SEC source: 0001225208-17-004775 · doc4.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document
February 28, 2016 Filed Mar 2, 2016 00:13 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	10,106	$30.23	$305,504.38	Disclosure SEC source: 0001225208-16-028814 · doc4.xml · nonDerivative · entry 3 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,609 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document
February 28, 2016 Filed Mar 2, 2016 00:13 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	5,044	$30.23	$152,480.12	Disclosure SEC source: 0001225208-16-028814 · doc4.xml · nonDerivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,715 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 28, 2016 Filed Mar 2, 2016 00:13 UTC	PFIZER INC PFE · Entity 2863	GrantCommon Stock	9,780	$0.00	$0.00	Disclosure SEC source: 0001225208-16-028814 · doc4.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,759 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 25, 2016 Filed Feb 26, 2016 20:05 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	69,337	$0.00 Strike: $30.59	$0.00	Disclosure SEC source: 0001225208-16-028382 · doc4.xml · derivative · entry 7 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,337 Underlying: Common Stock · 69,337 shares Expires 2023-02-25 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document
February 25, 2016 Filed Feb 26, 2016 20:05 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	77,586	$0.00 Strike: $30.59	$0.00	Disclosure SEC source: 0001225208-16-028382 · doc4.xml · derivative · entry 6 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,586 Underlying: Common Stock · 77,586 shares Expires 2021-02-25 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document
February 24, 2016 Filed Feb 26, 2016 20:05 UTC	PFIZER INC PFE · Entity 2863	Exercise / conversionStock Appreciation Rights · Derivative	110,981	$0.00 Strike: $18.90	$0.00	Disclosure SEC source: 0001225208-16-028382 · doc4.xml · derivative · entry 5 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,981 shares Expires 2016-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 24, 2016 Filed Feb 26, 2016 20:05 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	52,367	$29.67	$1,553,728.89	Disclosure SEC source: 0001225208-16-028382 · doc4.xml · nonDerivative · entry 3 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,979 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document
February 24, 2016 Filed Feb 26, 2016 20:05 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	25,410	$30.02	$762,808.20	Disclosure SEC source: 0001225208-16-028382 · doc4.xml · nonDerivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,346 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document
February 24, 2016 Filed Feb 26, 2016 20:05 UTC	PFIZER INC PFE · Entity 2863	Exercise / conversionCommon Stock	110,981	$18.90	$2,097,540.90	Disclosure SEC source: 0001225208-16-028382 · doc4.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document
February 26, 2015 Filed Feb 27, 2015 23:42 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	60,403	$0.00 Strike: $34.59	$0.00	Disclosure SEC source: 0001225208-15-006200 · doc4.xml · derivative · entry 9 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,403 Underlying: Common Stock · 60,403 shares Expires 2022-02-26 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document
February 26, 2015 Filed Feb 27, 2015 23:42 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	72,464	$0.00 Strike: $34.59	$0.00	Disclosure SEC source: 0001225208-15-006200 · doc4.xml · derivative · entry 8 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,464 Underlying: Common Stock · 72,464 shares Expires 2020-02-26 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document
February 25, 2015 Filed Feb 27, 2015 23:42 UTC	PFIZER INC PFE · Entity 2863	Exercise / conversionStock Appreciation Rights · Derivative	101,351	$0.00 Strike: $17.69	$0.00	Disclosure SEC source: 0001225208-15-006200 · doc4.xml · derivative · entry 7 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 101,351 shares Expires 2015-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.